Johnson & Johnson (JNJ) PT Raised to $160 at Stifel

RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)

July 18, 2024 6:14 AM EDT

RBC Capital analyst Shagun Singh reiterated an Outperform rating and $175.00 price target on Johnson & Johnson (NYSE: JNJ).

The analyst comments "JNJ's stock traded higher (+3.7%) post-Q2'24 beat. It maintained its FY24 adjusted operational sales growth outlook but lowered adjusted EPS to reflect M&A-related... More

Midday movers: Nvidia, TSMC, Five Below, Spirit Airlines and Eli Lilly fall

July 17, 2024 7:48 AM EDT

(Updated - July 17, 2024 11:30 AM EDT)

Investing.com -- U.S. stock futures fell sharply Wednesday, with the tech stocks in sharp retreat as the quarterly earnings season continues.

Here are some of the biggest U.S. stock movers today:

Taiwan Semiconductor Manufacturing (NYSE: TSM) stock fell 5% after Donald Trump, the Republican candidate for the U.S. presidency, said Taiwan should pay the U.S. for supplying defense equipment, putting the spotlight on the islands biggest company.

Nvidia (NASDAQ:... More

Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates

July 17, 2024 6:39 AM EDT

Johnson & Johnson (NYSE: JNJ) reported a robust second quarter, with both earnings and revenue surpassing Wall Street estimates.

The healthcare giant posted adjusted earnings per share (EPS) of $2.82, exceeding analyst predictions by $0.10, and a revenue of $22.45 billion, also topping the consensus estimate of $22.34 billion.

This performance represents a 4.3% increase in reported sales growth, with an operational growth of 6.6%.

The company's stock responded positively to the news, with shares rising 2.1% as investors reacted favorably... More

Johnson & Johnson (JNJ) Declares $1.24 Quarterly Dividend; 3.3% Yield

July 17, 2024 6:25 AM EDT

Johnson & Johnson (NYSE: JNJ) declared a quarterly dividend of $1.24 per share, or $4.96 annualized.

The dividend will be payable on September 10, 2024, to stockholders of record on August 27, 2024, with an ex-dividend date of August 26, 2024.

The annual yield on the dividend is 3.3... More

J&J beats Wall St estimates on strong drug sales ahead of Stelara competition

July 17, 2024 6:22 AM EDT

(This July 17 story has been corrected to clarify that the CFO did not suggest that pending Stelara insurance contracts would be 'favorable,' in paragraph 4)

By Patrick Wingrove and Bhanvi Satija

(Reuters) - Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.

Stelara has long been a key driver of revenue growth for J&J, with analysts forecasting sales of over $10 billion this year. But this could fall to about $7 billion in 2025 when as many as six... More

Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance

July 17, 2024 6:21 AM EDT

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.82, $0.10 better than the analyst estimate of $2.72. Revenue for the quarter came in at $22.45 billion versus the consensus estimate of $22.34 billion.

GUIDANCE:

Johnson & Johnson sees FY2024 EPS of $10.05, versus the consensus of... More

Stocks expected to have increasing option volume: JNJ ELV USB SYF CFG ALLY BE SAVE JBHT

July 17, 2024 6:00 AM EDT

Stocks expected to have increasing option volume: JNJ ELV USB SYF CFG ALLY BE SAVE JBHT

... More